利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.032 秒)

    Anti-IGF-I receptor antibody
    6.
    发明授权
    Anti-IGF-I receptor antibody 失效
    抗IGF-I受体抗体

    公开(公告)号：US07985842B2

    公开(公告)日：2011-07-26

    申请号：US12276586

    申请日：2008-11-24

    申请人： Rajeeva Singh ,  Daniel J. Tavares ,  Nancy E. Dagdigian

    发明人： Rajeeva Singh ,  Daniel J. Tavares ,  Nancy E. Dagdigian

    IPC分类号： C12P21/08 ,  C07K16/00 ,  A61K39/395 ,  A61K49/00 ,  C07H21/04 ,  G01N33/574

    CPC分类号： A61K39/39558 ,  A61K31/337 ,  A61K31/4745 ,  A61K39/39541 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2863 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

    摘要： Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.

    摘要翻译： 抗体，人源化抗体，表面抗体，抗体片段，衍生抗体，以及这些分子与细胞毒性剂的结合物，其特异性结合并抑制胰岛素样生长因子-I受体拮抗IGF-1的作用，并且基本上没有 对胰岛素样生长因子-I受体的激动剂活性。 这些分子可以与细胞毒性剂结合，用于治疗表达IGF-1受体水平升高的肿瘤，例如乳腺癌，结肠癌，肺癌，卵巢癌，滑膜肉瘤和胰腺癌。 这些分子也可以用于体外和体内诊断用途的标记，例如在表达IGF-1受体水平升高的肿瘤的诊断和成像中。

    CD20 antibodies and uses thereof
    7.
    发明授权
    CD20 antibodies and uses thereof 有权
    CD20抗体及其用途

    公开(公告)号：US09175086B2

    公开(公告)日：2015-11-03

    申请号：US13024671

    申请日：2011-02-10

    申请人： Jutta Deckert ,  Daniel J. Tavares ,  Peter U. Park

    发明人： Jutta Deckert ,  Daniel J. Tavares ,  Peter U. Park

    IPC分类号： A61K39/395 ,  C07K16/28 ,  C07K16/30 ,  A61K47/48 ,  A61K51/10 ,  G01N33/574 ,  A61K39/00

    CPC分类号： C07K16/2887 ,  A61K39/39541 ,  A61K47/6817 ,  A61K47/6819 ,  A61K47/6849 ,  A61K51/1027 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/30 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92 ,  C07K2319/55 ,  G01N33/57426

    摘要： CD20 is a transmembrane protein of the tetra-spanin family expressed on the surface of B-cells from peripheral blood as well as lymphoid tissues. CD20 expression persists from the early pre-B cell stage until the plasma cell differentiation stage. In addition to expression in normal B-cells, CD20 is expressed in B-cell derived malignancies such as non-Hodgkin's lymphoma (NHL) and B-cell chronic lymphocytic leukemia (CLL). The present invention includes anti-CD20 antibodies and antigen-binding fragments thereof comprising a light chain variable region and a heavy chain variable region, wherein the CDR-L1, CDR-L2, and CDR-L3 of said light chain variable region comprise the amino acid sequences of SEQ ID NOs: 23-25, respectively, and wherein the CDR-H1, CDR-H2, and CDR-H3 of said heavy chain variable region comprise the amino acid sequences of SEQ ID NOs: 26-28, respectively.

    摘要翻译： CD20是来自外周血和淋巴组织的B细胞表面上表达的四跨连锁蛋白家族的跨膜蛋白。 CD20表达从早期B细胞前期持续到血浆细胞分化阶段。 除了在正常B细胞​​中表达外，CD20在B细胞衍生的恶性肿瘤如非霍奇金淋巴瘤（NHL）和B细胞慢性淋巴细胞白血病（CLL）中表达。 本发明包括抗CD20抗体及其包含轻链可变区和重链可变区的抗原结合片段，其中所述轻链可变区的CDR-L1，CDR-L2和CDR-L3包含氨基 分别为SEQ ID NO：23-25的酸序列，并且其中所述重链可变区的CDR-H1，CDR-H2和CDR-H3分别包含SEQ ID NO：26-28的氨基酸序列。

    ANTI-IGF-I RECEPTOR ANTIBODY
    8.
    发明申请
    ANTI-IGF-I RECEPTOR ANTIBODY 失效
    抗IGF-I受体抗体

    公开(公告)号：US20090155165A1

    公开(公告)日：2009-06-18

    申请号：US12276586

    申请日：2008-11-24

    申请人： Rajeeva SINGH ,  Daniel J. Tavares ,  Nancy E. Dagdigian

    发明人： Rajeeva SINGH ,  Daniel J. Tavares ,  Nancy E. Dagdigian

    IPC分类号： A61K51/00 ,  C07K16/18 ,  C12N15/11 ,  C12N15/00 ,  C12N5/06 ,  C12P21/00 ,  A61K49/00

    CPC分类号： A61K39/39558 ,  A61K31/337 ,  A61K31/4745 ,  A61K39/39541 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2863 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

    摘要： Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.

    摘要翻译： 抗体，人源化抗体，表面抗体，抗体片段，衍生抗体，以及这些分子与细胞毒性剂的结合物，其特异性结合并抑制胰岛素样生长因子-I受体拮抗IGF-1的作用，并且基本上没有 对胰岛素样生长因子-I受体的激动剂活性。 这些分子可以与细胞毒性剂结合，用于治疗表达IGF-1受体水平升高的肿瘤，例如乳腺癌，结肠癌，肺癌，卵巢癌，滑膜肉瘤和胰腺癌。 这些分子也可以用于体外和体内诊断用途的标记，例如在表达IGF-1受体水平升高的肿瘤的诊断和成像中。

    Anti-IGF-I receptor antibody
    9.
    发明授权
    Anti-IGF-I receptor antibody 有权
    抗IGF-I受体抗体

    公开(公告)号：US07538195B2

    公开(公告)日：2009-05-26

    申请号：US10170390

    申请日：2002-06-14

    申请人： Rajeeva Singh ,  Daniel J. Tavares ,  Nancy E. Dagdigian

    发明人： Rajeeva Singh ,  Daniel J. Tavares ,  Nancy E. Dagdigian

    IPC分类号： C12P21/08 ,  C07K16/00 ,  A61K39/395 ,  A61K49/00 ,  C07H21/04 ,  G01N33/574

    CPC分类号： A61K39/39558 ,  A61K31/337 ,  A61K31/4745 ,  A61K39/39541 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2863 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

    摘要： Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.

    摘要翻译： 抗体，人源化抗体，表面抗体，抗体片段，衍生抗体，以及这些分子与细胞毒性剂的结合物，其特异性结合并抑制胰岛素样生长因子-I受体拮抗IGF-1的作用，并且基本上没有 对胰岛素样生长因子-I受体的激动剂活性。 这些分子可以与细胞毒性剂结合，用于治疗表达IGF-1受体水平升高的肿瘤，例如乳腺癌，结肠癌，肺癌，卵巢癌，滑膜肉瘤和胰腺癌。 这些分子也可以用于体外和体内诊断用途的标记，例如在表达IGF-1受体水平升高的肿瘤的诊断和成像中。

    Anti-IGF-I receptor antibodies, DNAs, vectors, host cells and genetic constructs
    10.
    发明授权
    Anti-IGF-I receptor antibodies, DNAs, vectors, host cells and genetic constructs 有权
    抗IGF-I受体抗体，DNAs，载体，宿主细胞和遗传构建体

    公开(公告)号：US08268617B2

    公开(公告)日：2012-09-18

    申请号：US12547543

    申请日：2009-08-26

    申请人： Rajeeva Singh ,  Daniel J. Tavares ,  Nancy E. Dagdigian

    发明人： Rajeeva Singh ,  Daniel J. Tavares ,  Nancy E. Dagdigian

    IPC分类号： C12N5/16 ,  C12N5/07 ,  C12N15/113 ,  C07H21/04 ,  C07K16/28

    CPC分类号： A61K39/39558 ,  A61K31/337 ,  A61K31/4745 ,  A61K39/39541 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2863 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

    摘要： DNAs, vectors, host cells and genetic constructs of antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.

    摘要翻译： DNA，载体，宿主细胞和抗体的遗传构建体，人源化抗体，表面抗体，抗体片段，衍生化抗体，以及这些分子与细胞毒性剂的缀合物，其特异性结合并抑制胰岛素样生长因子-I受体拮抗 IGF-I的作用并且对胰岛素样生长因子-I受体基本上没有激动剂活性。 这些分子可以与细胞毒性剂结合，用于治疗表达IGF-1受体水平升高的肿瘤，例如乳腺癌，结肠癌，肺癌，卵巢癌，滑膜肉瘤和胰腺癌。 这些分子也可以用于体外和体内诊断用途的标记，例如在表达IGF-1受体水平升高的肿瘤的诊断和成像中。